Atovaquone suspension for treatment of Pneumocystis carinii pneumonia in HIV-infected patients

被引：17

作者：

Rosenberg, DM

McCarthy, W

Slavinsky, J

Chan, CKN

Montaner, J

Braun, J

Dohn, MN

Caldwell, PT

机构：

[1] Glaxo Wellcome Res & Dev Ltd, Worldwide Epidemiol, Div Epidemiol, Greenford UB6 OHE, Middx, England

[2] AIDS Res Consortium Atlanta, Atlanta, GA USA

[3] Louisiana State Univ, Med Ctr, Div HIV, New Orleans, LA USA

[4] Toronto Hosp, Toronto, ON M5T 2S8, Canada

[5] St Pauls Hosp, Dept Infect Dis, Vancouver, BC V6Z 1Y6, Canada

[6] Liberty Med, New York, NY USA

[7] SAMS, Ambridge, PA USA

[8] Glaxo Wellcome Inc, Res Triangle Pk, NC 27709 USA

来源：

AIDS | 2001年 / 15卷 / 02期

关键词：

atovaquone suspension; opportunistic infections; Pneumocystis carinii pneumonia;

D O I：

10.1097/00002030-200101260-00010

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Objective: To describe clinical experience with atovaquone suspension for the treatment of Pneumocystis carinii pneumonia (PCP) in HIV-infected patients. Design: A retrospective chart review. Methods: The medical records of 54 HIV-infected patients with PCP treated with atovaquone were examined. The outcomes of 34 patients treated with atovaquone suspension (750 mg twice a day) were compared with those of 20 patients treated with atovaquone tablets (750 mg three times a day). Results: The proportion of patients successfully treated was similar with the suspension (74%) and tablet (70%) formulations of atovaquone. The proportion of patients with an inadequate response to therapy was lower for patients treated with atovaquone suspension (15%) than tablets (30%). Both formulations were well tolerated. Conclusion: Atovaquone suspension is effective and well tolerated for the treatment of PCP. (C) 2001 Lippincott Williams & Wilkins.

引用

页码：211 / 214

页数：4

共 12 条

[1]

CHAISSON R, 1999, MANAGEMENT PNEUMOCYS

[2] Atovaquone suspension compared with aerosolized pentamidine for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides [J].

Chan, C ;

Montaner, J ;

Lefebvre, EA ;

Morey, G ;

Dohn, M ;

McIvor, RA ;

Scott, J ;

Marina, R ;

Caldwell, P .

JOURNAL OF INFECTIOUS DISEASES, 1999, 180 (02) :369-376

[3] ORAL ATOVAQUONE COMPARED WITH INTRAVENOUS PENTAMIDINE FOR PNEUMOCYSTIS-CARINII PNEUMONIA IN PATIENTS WITH AIDS [J].

DOHN, MN ;

WEINBERG, WG ;

TORRES, RA ;

FOLLANSBEE, SE ;

CALDWELL, PT ;

SCOTT, JD ;

GATHE, JC ;

HAGHIGHAT, DP ;

SAMPSON, JH ;

SPOTKOV, J ;

DERESINSKI, SC ;

MEYER, RD ;

LANCASTER, DJ ;

FRAME, PT ;

MOHSENIFAR, Z ;

BUCKLEY, RM ;

CHEUNG, T ;

HYLAND, R ;

CHAN, C ;

LANG, W ;

MILDVAN, D ;

GREENBERG, SB ;

CRAVEN, D ;

HIRSCH, M ;

ELSADR, W ;

JOSEPH, P ;

HARDY, D ;

BROWN, N ;

ROGERS, M .

ANNALS OF INTERNAL MEDICINE, 1994, 121 (03) :174-180

[4] Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both [J].

El-Sadr, WM ;

Murphy, RL ;

Yurik, RM ;

Luskin-Hawk, R ;

Cheung, TW ;

Balfour, HH ;

Eng, R ;

Hooton, TM ;

Kerkering, TM ;

Schutz, M ;

van der Horst, C ;

Hafner, R .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (26) :1889-1895

[5]

FALLOON J, 1995, 2 NAT C HUM RETR

[6]

*GLAX WELLC INC, MEPRON PACK INS

[7] COMPARISON OF ATOVAQUONE (566C80) WITH TRIMETHOPRIM-SULFAMETHOXAZOLE TO TREAT PNEUMOCYSTIS-CARINII PNEUMONIA IN PATIENTS WITH AIDS [J].

HUGHES, W ;

LEOUNG, G ;

KRAMER, F ;

BOZZETTE, SA ;

SAFRIN, S ;

FRAME, P ;

CLUMECK, N ;

MASUR, H ;

LANCASTER, D ;

CHAN, C ;

LAVELLE, J ;

ROSENSTOCK, J ;

FALLOON, J ;

FEINBERG, J ;

LAFON, S ;

ROGERS, M ;

SATTLER, F .

NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (21) :1521-1527

[8] Pneumocystis carinii [J].

Levine, SJ .

CLINICS IN CHEST MEDICINE, 1996, 17 (04) :665-+

[9] Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection [J].

Palella, FJ ;

Delaney, KM ;

Moorman, AC ;

Loveless, MO ;

Fuhrer, J ;

Satten, GA ;

Aschman, DJ ;

Holmberg, SD .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (13) :853-860

[10] PREDICTORS FOR FAILURE OF PNEUMOCYSTIS-CARINII PNEUMONIA PROPHYLAXIS [J].

SAAH, AJ ;

HOOVER, DR ;

PENG, Y ;

PHAIR, JP ;

VISSCHER, B ;

KINGSLEY, LA ;

SCHRAGER, LK .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 273 (15) :1197-1202

← 1 2 →